TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05789056: A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton Syndrome

Sponsor: Quoin Pharmaceuticals · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$7,290,720

Rescue Site Savings

+$4,819,976

Unlock Full NCT05789056 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05789056 Rescue Dossier →